Mangoceuticals (MGRX) “announced the filing of a Patent Cooperation Treaty (PCT) international application on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024. This PCT filing directly extends the intellectual property portfolio supporting the results highlighted in the February 23, 2026 press release, including zero respiratory-related mortality across 29,000 birds in commercial field trials and statistically significant prophylactic benefit against highly pathogenic H5N1 in the ICAR-NIHSAD controlled challenge study.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- Mangoceuticals Highlights Promising MGX-0024 Poultry Antiviral Data
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Here’s Why Mangoceuticals Stock (MGRX) Rocketed Today
- Mangoceuticals Accelerates Growth With New Testosterone Therapy Program
- Mangoceuticals Receives Nasdaq Notice on Minimum Bid Price